864245-40-9

Upstream product

• 403-19-0 2-fluoro-4-nitrophenol 
• 864245-38-5 6-(2-Fluoro-4-nitrophenoxy)pyrimidin-4-ylamine 
• 868733-15-7 4-chloro-6-(2-fluoro-4-nitrophenoxy)pyrimidine 
• 864245-39-6 Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-nitrophenoxy)pyrimidin-4-yl]amide 

Downstream Products

• 1020535-58-3 N-(6-(2-fluoro-4-(4,4,4-trifluoro-3-(4-fluorophenylamino)butanamido)phenoxy)pyrimidin-4-yl)pyrrolidine-1-carboxamide 
• 1020535-60-7 N-(3-fluoro-4-(6-(pyrrolidine-1-carboxamido)pyrimidin-4-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamide 
• 1020536-42-8 N-(6-(4-(1-ethoxy-2,2,2-trifluoroethylamino)-2-fluorophenoxy)pyrimidin-4-yl)pyrrolidine-1-carboxamide 
• 864245-49-8 N-(3-fluoro-4-{6-[(pyrrolidine-1-carbonyl)amino]pyrimidin-4-yloxy}phenyl)malonic acid benzyl ester 

Relevant academic research and scientific papers

KINASE INHIBITORS AND USES THEREOF

The present invention relates to compounds of the general formula (A) and pharmaceutical compositions thereof that inhibit protein tyrosine activity. In particular the invention relates to said compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signalling, for example, the inhibition of VEGF receptor signalling and HGF receptor signalling. Said compounds and compositions are useful for the treatment of cell proliferative diseases and conditions.

SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.